Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DataMEDS AIMEDS -3.35% Debt-to-EBITDA is -1.36 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 90 Medical Distribution companies, DataMEDS AI ranks worse than 1111110% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for DataMEDS AI's Debt-to-EBITDA or its related term are showing as below:
MEDS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.11 Med: -0.27 Max: -0.12
Current: -0.42
During the past 4 years, the highest Debt-to-EBITDA Ratio of DataMEDS AI was -0.12. The lowest was -5.11. And the median was -0.27.
MEDS's Debt-to-EBITDA is ranked worse than 100% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs MEDS: -0.42
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
DataMEDS AI Debt-to-EBITDA Related Terms
DataMEDS AI Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for DataMEDS AI's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDS vs HEWA, BLMH, PMHS: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, DataMEDS AI's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DataMEDS AI Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, DataMEDS AI's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DataMEDS AI's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
DataMEDS AI (MEDS) has a Debt-to-EBITDA of -1.36 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on DataMEDS AI. According to the industry distribution chart, DataMEDS AI ranks #999999 out of 90 companies in the Medical Distribution industry.
Is DataMEDS AI's Debt-to-EBITDA too high?
DataMEDS AI's current Debt-to-EBITDA is -1.36. Based on the distribution chart, DataMEDS AI ranks #999999 out of 90 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers.
How does DataMEDS AI's Debt-to-EBITDA compare to HEWA and BLMH?
According to the Medical Distribution industry distribution chart, DataMEDS AI ranks #999999 out of 90 companies for Debt-to-EBITDA. This places DataMEDS AI in the lower half of its industry. The industry median Debt-to-EBITDA is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on DataMEDS AI. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DataMEDS AI's current Debt-to-EBITDA is -1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DataMEDS AI stock overvalued right now?
DataMEDS AI (MEDS) has a current Debt-to-EBITDA of -1.36. The current Debt-to-EBITDA is -1.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For DataMEDS AI (MEDS), the current Debt-to-EBITDA is -1.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDS has been successfully added to your 
